Clinical Trial of IL-12 for cancer patients

Japanese Journal of Cancer and Chemotherapy

Volumn 25, Issue 1, 1998, Pages 177-184

  Ohe, Yuichiro ^a   Kasai, Takashi ^b   Heike, Yuji ^c   Saijo, Nagahiro ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; INTERLEUKIN 12;

CLINICAL TRIAL; DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; PHYSIOLOGY; REVIEW;

BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERLEUKIN-12; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MELANOMA;

EID: 84874315456     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kobayashi, M., Fitz, L., Ryan, M. et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170:827-845, 1989.
2. Trinchieri, G.: Interleukin-12 : a cytokine produced by antigen-presenting cells with im-munoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008-4027, 1994.
3. Wong, H. L., Wilson, D. E., Jenson, J. C. et al: Characterization of a factor (s) which syner-gizes with recombinant interleukin 2 in promoting allogenic human cytolytic T-lymphocyte responses in vitro. Cell Immunol. Ill: 39-54, 1988.
4. Wolf, S. F., Temple, P. A., Kobayashi.M. et al: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146:3074-3081,1991.
5. Gubler, U., Chua, A. O., Schoenhaut.D.S. et al: Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88:4143-4147, 1991.
6. Gearing, D. P. and Cosman, D.: Homology of the p40 subunit of natural killer stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 66 :9-10, 1991.
7. Sieburth, D., Jabs, E. W., Warrington, J. A. et al: Assignment of NKSF/IL 12, a unique cytokine composed of two unrelated subunits, to chromosomes 3 and 5. Genomics 14:59-62, 1992.
8. Chua, A. O., Chizzonite, R., Desai, B. B. et al: Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp 130. J. Immunol. 153:128-136, 1994.
9. Presky, D.H., Gubler, U., Chizzonite, R.A. et al:IL-12 receptors and receptor antagonists. Res. Immunol. 146: 439-444, 1995.
10. Scott, P.: IL-12 : initiation cytokine for cell-mediated immunity. Science 260:496-497, 1993.
11. Germann, T., Gately, M. K., Schoenhaut, D. S. et al: Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Thl) but not on Th2 cells. Eur. J. Immunol. 23:1762-1770, 1993.
12. Romagnani, S.: Induction of Thl and Th2 responses: a key role for the 'natural' immune response? Immunol. Today 13:379-381, 1992.
13. Hsieh, C. S., Macatonia, S. F., Tripp, C. S. et al: Development of Thl CD4+ T cells through IL-12 production by Listeria-mdaced macrophages. Science 260: 547-549, 1993.
14. Murphy, E.E., Terres, G., Macatonia, S. E. et al: B7 and interleukin 12 cooperate for proliferation and interferon y production by mouse T helper clones that are unresponsive to B 7 costimulation. J Exp. Med. 180:223-231, 1994.
15. Meyaard, L., Hovenkamp, E., Otto, S. A. et al: IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J. Immunol. 156:2776-2782, 1996.
16. Lamers, C, Gratama, J., Ogilvie, A. et al: Exogenous IL-12 induces in vivo IL-10 production, followed by downregulation of IL-12 activities. Proc. ASCO 16: 435 a, 1997.
17. Gately, M. K., Warrier, R. R., Honasoge, S. et al: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-y in vivo. Int. Immunol. 6 :157-167, 1993.
18. Sgadari, C, Angiolillo, A. L. and Tosato, G.: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877-3882, 1996.
19. Kiniwa, M., Gately, M., Gubler, U. et al: Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J. Clin. Invest. 90:262-266, 1992.
20. Schoenhaut, D. S., Chua, A. O., Wolitzky, A. G. et al: Cloning and expression of murine IL-12. J. Immunol. 148: 3433-3440, 1992.
21. Brunda, M. J., Luistro, L., Warrier, R. R. et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223-1230, 1993.
22. Nastala, C. L., Edington, H. D., McKinney, T. G. et al: Recombinant IL-12 administration induces tumor regression in association with IFN-y production. J. Immunol. 153:1697-1706, 1994.
23. Brunda, M. J., Luistro, L., Rumennik, L. et al: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol, msuppl.) : S16-S21, 1996.
24. Atkins, M. B., Robertson, M., Gordon, M. S. et al: Phase I evaluation of intervenous recombinant human interleukin-12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417, 1997.
25. Cohen, J.: IL-12 deaths: explantation and a puzzle. Science 270:908, 1995.
26. Goey, S. H., Aulitzky, W., Ogilvie, A.: Recombinant human interleukin-12 (IL-12) in metastatic renal cell cancer (RCC) patients (pts) : a phase I study. Proc. ASCO 16 : 435 a, 1997.
27. Herberman, R. B.: Design of clinical trials with biological response modifiers. Cancer Treat. Rep. 69 :1161-1164, 1985.
28. Maluish, A. E. and Herberman.R.B.: Assessment of biological responses: what to measure and when. Cancer Treat. Rep. 69:1165-1169, 1985.
29. Tahara, H., Zitvgel, L., Storkus, W. J. et al: Antitumor effects in patients with melanoma, head and neck and breast cancer in a phasel/II clinical trial of interleukin-12 (IL-12) gene therapy. Proc. ASCO 16: 438 a, 1997.